C-reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives

Hypertension Research

Volumn 29, Issue 6, 2006, Pages 411-415

  Conen, David ^a   Dieterle, Thomas ^a   Utech, Katrin ^a   Rimner, Miriam ^a   Martina, Benedict ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Ambulatory blood pressure monitoring; B type natriuretic peptide; C reactive protein; Hypertension; Inflammation

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTPATIENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SUSTAINED HYPERTENSION; WHITE COAT HYPERTENSION;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OFFICE VISITS;

EID: 33746279974     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.411     Document Type: Article

References (23)

1. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
2. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
3. Schillaci G, Pirro M, Gemelli F, et al: Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846.
4. Niu K, Hozawa A, Fujita K, et al: Influence of leisure-time physical activity on the relationship between C-reactive protein and hypertension in a community-based elderly population of Japan: the Tsurugaya project. Hypertens Res 2005; 28: 747-754.
5. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C: Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens 2004; 17: 568-573.
6. Maeda K, Yasunari K, Watanabe T, Nakamura M: Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure. Hypertens Res 2005; 28: 755-761.
7. Blake GJ, Rifai N, Buring JE, Ridker PM: Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
8. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
9. Verdecchia P, Staessen JA, White WB, Imai Y, O'Brien ET: Properly defining white coat hypertension. Eur Heart J 2002; 23: 106-109.
10. Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
11. Nishikimi T, Yoshihara F, Morimoto A, et al: Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
12. Wang TJ, Larson MG, Levy D, et al: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
13. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2571.
14. Palmieri V, Dahlof B, DeQuattro V, et al: Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625-1632.
15. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
16. Pearson TA, Mensah GA, Alexander RW, et al: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
17. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM: Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674-682.
18. Nakashima T, Yamano S, Sasaki R, et al: White-coat hypertension contributes to the presence of carotid arteriosclerosis. Hypertens Res 2004; 27: 739-745.
19. Wang TJ, Larson MG, Levy D, et al: Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
20. Wu AH, Smith A, Wieczorek S, Mather JF, et al: Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003; 92: 628-631.
21. Conen D, Pfisterer M, Martina B: Substantial intraindividual variability of BNP concentrations in patients with hypertension. J Hum Hypertens; advance online publication, February 16, 2006; doi: 2010.1038/ sj.jhh.1001988.
22. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Porcellati C: White-coat hypertension. Lancet 1996; 348: 1444-1446.
23. Verdecchia P, Reboldi GP, Angeli F, et al: Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203-208.